Show simple item record

dc.contributor.authorWorld Health Assembly, 45
dc.coverage.spatialGenevaEN
dc.date.accessioned2015-06-14T16:09:52Z
dc.date.available2015-06-14T16:09:52Z
dc.date.issued1992
dc.identifier.govdocA45/A/Conf.Paper No.4
dc.identifier.urihttp://www.who.int/iris/handle/10665/175636
dc.description(‎Agenda item 19.2)‎EN
dc.language.isoenEN
dc.publisherWorld Health OrganizationEN
dc.subjectPharmaceutical productsEN
dc.subject.meshPharmaceutical PreparationsEN
dc.subject.meshDrug IndustryEN
dc.subject.meshMarketingEN
dc.subject.meshEthics, PharmacyEN
dc.subject.meshHealth PlanningEN
dc.subject.meshHealth PolicyEN
dc.subject.meshWorld Health OrganizationEN
dc.titleWHO ethical criteria for medicinal drug promotion: amendments proposed to Resolution EB89.R2 contained in document EB89/1992/REC/1EN
dc.typeGoverning body documentsEN
dc.subject.meshqualifierethicsEN


Files in this item

Thumbnail

This item appears in the following Collection(‎s)‎

Show simple item record